Recordati S.p.A. Company Profile

Background

Overview

Recordati S.p.A., established in 1926, is an international pharmaceutical group headquartered in Milan, Italy. The company specializes in the research, development, manufacturing, and marketing of pharmaceutical products, with a strong emphasis on treatments for rare diseases. Recordati operates in approximately 150 countries, offering a diverse portfolio that includes both proprietary and licensed products.

Mission and Vision

Recordati's mission is to develop and commercialize medicines that enhance the quality of life for individuals affected by common and rare diseases. The company's vision is to be a global leader in providing innovative treatments, focusing on unmet medical needs and improving patient outcomes worldwide.

Primary Area of Focus

The company's primary focus areas include:

Specialty and Primary Care: Addressing therapeutic areas such as cardiovascular, urological, gastrointestinal, and respiratory diseases.

Rare Diseases: Developing treatments for rare and complex conditions, particularly in metabolic, endocrinology, and hematology-oncology.

Industry Significance

Recordati holds a significant position in the pharmaceutical industry, particularly in the rare diseases segment. Its global presence and comprehensive product portfolio enable it to address a wide range of therapeutic needs, contributing to advancements in patient care and treatment accessibility.

Key Strategic Focus

Core Objectives

Expansion of Rare Diseases Portfolio: Enhancing the range of treatments available for rare and complex diseases.

Geographical Diversification: Strengthening market presence in emerging and underserved regions.

Innovation and Research: Investing in research and development to bring new, effective treatments to market.

Specific Areas of Specialization

Metabolic Disorders: Focusing on treatments for rare metabolic conditions.

Endocrinology: Developing therapies for rare endocrine diseases.

Hematology-Oncology: Addressing rare blood and cancer-related disorders.

Key Technologies Utilized

Biologics: Utilizing biologic therapies for targeted treatments.

Advanced Manufacturing: Employing state-of-the-art facilities for drug production.

Primary Markets Targeted

United States: A leading market for Recordati's products.

Europe: Including Italy and other European countries.

Emerging Markets: Expanding presence in regions such as Asia, Africa, and Latin America.

Financials and Funding

Funding History

Recordati has experienced consistent growth, with revenues reaching €2.34 billion in 2024, marking a 12.4% increase from the previous year.

Recent Funding Rounds

In 2018, CVC Capital Partners acquired a 51.8% stake in Recordati for approximately €3 billion, providing significant capital for expansion and strategic initiatives.

Notable Investors

CVC Capital Partners: Majority shareholder since 2018.

Utilization of Capital

Acquisitions: Enhancing the rare diseases portfolio, such as the acquisition of EUSA Pharma in 2021.

Research and Development: Investing in innovative treatments and expanding the product pipeline.

Geographical Expansion: Strengthening market presence in key regions.

Pipeline Development

Key Pipeline Candidates

Enjaymo®: Acquired global rights in 2024; a biologic treatment for cold agglutinin disease.

Isturisa®: Approved in China for Cushing's Syndrome; supplemental new drug application submitted in the U.S.

Stages of Clinical Trials or Product Development

Enjaymo®: Marketed in the U.S., Europe, and Japan; integration into Recordati's portfolio underway.

Isturisa®: Marketed in the U.S. and Europe; expansion into new markets.

Target Conditions

Enjaymo®: Cold agglutinin disease.

Isturisa®: Cushing's Syndrome.

Relevant Timelines for Anticipated Milestones

Enjaymo®: Integration and commercialization in new markets.

Isturisa®: Regulatory approvals and market launches in additional regions.

Technological Platform and Innovation

Proprietary Technologies

Biologic Therapies: Developing and commercializing biologic treatments for rare diseases.

Significant Scientific Methods

Advanced Manufacturing Techniques: Ensuring high-quality production standards.

Clinical Research: Conducting rigorous studies to support product efficacy and safety.

Leadership Team

Executive Profiles

Andrea Recordati: Chairman; previously served as CEO, leading strategic initiatives and overseeing company growth.

Rob Koremans: Chief Executive Officer; joined in 2021, focusing on operational excellence and global expansion.

Luigi La Corte: Chief Financial Officer; responsible for financial strategy and management.

Alessandra Abate: Group Chief People and Culture Officer; leading human resources and organizational development.

Competitor Profile

Market Insights and Dynamics

The global pharmaceutical market is characterized by rapid innovation, regulatory challenges, and a growing emphasis on personalized medicine. The rare diseases segment is expanding, driven by increased awareness and demand for specialized treatments.

Competitor Analysis

Novartis: A global leader in rare diseases, offering a broad portfolio of treatments.

Sanofi: Engaged in rare disease therapies, with a focus on biologics.

Alexion Pharmaceuticals: Specializes in rare and ultra-rare diseases, with a strong pipeline.

Strategic Collaborations and Partnerships

Enjaymo® Acquisition: Acquired global rights from Sanofi, enhancing rare disease portfolio.

Isturisa® Expansion: Collaborations for market entry in China and the U.S.

Operational Insights

Recordati's integrated operations, from R&D to commercialization, provide a competitive edge in delivering specialized treatments efficiently.

Strategic Opportunities and Future Directions